Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 6/20 | 0.57 |
| ▸ | CA1 | P00915 | 5/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.50 |
| ▸ | HPGD | P15428 | 3/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 4/20 | 0.46 |
| ▸ | CA9 | Q16790 | 4/20 | 0.46 |
| ▸ | CA3 | P07451 | 1/20 | 0.46 |
| ▸ | CA4 | P22748 | 1/20 | 0.46 |
| ▸ | CA6 | P23280 | 1/20 | 0.46 |
| ▸ | CA5A | P35218 | 1/20 | 0.46 |
| ▸ | CA7 | P43166 | 1/20 | 0.46 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3471628 | 0.84 | POLB (0.61) | CA2CA1HSD17B10HPGDALOX15 | |
| SCHEMBL1045638 | 0.83 | POLB (0.50) | CA2CA1HSD17B10HPGDALOX15 | |
| SCHEMBL1805528 | 0.83 | POLB (0.50) | CA2CA1HSD17B10HPGDALOX15 | |
| SCHEMBL30483899 | 0.83 | POLB (0.50) | CA2CA1HSD17B10HPGDALOX15 | |
| SCHEMBL5194623 | 0.83 | CA2 (0.52) | CA2CA1HSD17B10HPGDALOX15 | |
| SCHEMBL29852349 | 0.80 | CA1 (0.53) | CA2CA1HPGDALOX15ALDH1A1 | |
| SCHEMBL2127269 | 0.80 | CA1 (0.53) | CA2CA1HPGDALOX15ALDH1A1 | |
| SCHEMBL27466384 | 0.79 | CA1 (0.48) | CA2CA1HSD17B10HPGDALOX15 | |
| SCHEMBL17913250 | 0.79 | CA2 (0.51) | CA2CA1HSD17B10HPGDALOX15 | |
| SCHEMBL1645034 | 0.78 | CA1 (0.47) | CA2CA1CA12CA9CA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8404036-B2 | Water-soluble near-infrared absorbing coloring matters and aqueous inks containing same | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2013-03-26 | — | — | US | disclosed |
| US-20110123784-A1 | WATER-SOLUBLE NEAR-INFRARED ABSORBING COLORING MATTERS AND AQUEOUS INKS CONTAINING SAME | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2011-05-26 | — | — | US | disclosed |
| US-7098212-B2 | Piperazine derivatives | BLUMBERG LAURA C | 2006-08-29 | — | — | US | disclosed |
| EP-1583533-A1 | USE OF PIPERAZINE DERIVATIVES AS CCR1 ANTAGONISTS | Pfizer Products Inc. (US) | 2005-10-12 | — | — | EP | disclosed |
| CN-1575283-A | Piperazine derivatives having CCR1 receptor antagonist activity | PFIZER PROD INC (US) | 2005-02-02 | — | — | CN | disclosed |
| EP-1438298-A1 | PIPERAZINE DERIVATIVES WITH CCR1 RECEPTOR ANTAGONIST ACTIVITY | Pfizer Products Inc. (US) | 2004-07-21 | — | — | EP | disclosed |
| US-20040092529-A1 | Methods of using piperazine derivatives | PFIZER INC | 2004-05-13 | — | — | US | disclosed |
| WO-2004039376-A1 | USE OF PIPERAZINE DERIVATIVES AS CCR1 ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2004-05-13 | — | — | WO | disclosed |
| US-6727359-B2 | REACTING PHENOXIDE SULFONYLCHLORIDE AND ACETOACETAMIDE-N-SULFONYL PHENOXIDE AND AMMONIA USING CATALYST | BDL CORPORATION | 2004-04-27 | — | — | US | disclosed |
| US-20040034034-A1 | Novel piperazine derivatives | BLUMBERG LAURA C (US) | 2004-02-19 | — | — | US | disclosed |
| WO-2003035627-A1 | PIPERAZINE DERIVATIVES WITH CCR1 RECEPTOR ANTAGONIST ACTIVITY | PFIZER PRODUCTS INC. (US) | 2003-05-01 | — | — | WO | disclosed |
| US-20030065172-A1 | Composition comprising 6-methyl-3,4dihydro-1,2,3-oxathiazin-4-one-2,2-dioxide, its salts, preparation thereof and uses therefor | BDL CORPORATION | 2003-04-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040092529-A1 | Methods of using piperazine derivatives | CCR1, CCR3, CCR5 | CA2 1511/4885CA1 2079/4885HSD17B10 2053/4885 |
| US-20030065172-A1 | Composition comprising 6-methyl-3,4dihydro-1,2,3-oxathiazin-4-one-2,2-dioxide, its salts, preparation thereof and uses therefor | PDXK, ITK, KHK | CA2 1215/4885CA1 2380/4885HSD17B10 1156/4885 |
| US-20040034034-A1 | Novel piperazine derivatives | CCR1, CCRL2, CCR5 | CA2 2332/4885CA1 3361/4885HSD17B10 2280/4885 |
| US-20110123784-A1 | WATER-SOLUBLE NEAR-INFRARED ABSORBING COLORING MATTERS AND AQUEOUS INKS CONTAINING SAME | IK, RB1, COL1A1 | CA2 1279/4885CA1 798/4885HSD17B10 2848/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.